Morphosys (MOR) has released an update.
MorphoSys AG is set to showcase new Phase 3 data on pelabresib for treating myelofibrosis at the ASCO Annual Meeting, alongside additional findings from a Phase 2 study of tulmimetostat. The presentations will include significant efficacy and safety results for pelabresib in combination with ruxolitinib, and tulmimetostat as a treatment for advanced tumors. This announcement highlights MorphoSys’s ongoing efforts to advance cancer treatment through innovative drug development.
For further insights into MOR stock, check out TipRanks’ Stock Analysis page.
